“Libido” collapses two different mechanisms in casual usage: the central nervous-system signal that produces desire and arousal, and the peripheral vascular response that produces an erection. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are well-characterised for the vascular side and aren’t peptides - they’re standard sexual-medicine pharmacology. The peptide angle here is the central one: PT-141 directly, and MT-II as a side-effect of its melanocortin agonism.
This page sorts compounds by what they actually do, when they fit, and where the stacking lines are. For the receptor-level explanation see Melanocortin Map; for the broader hard-conflict / timing list see Stacking Safety Quick Reference.
Central vs vascular - the load-bearing distinction
| Mechanism | Compound | What it does | What it doesn’t |
|---|---|---|---|
| Central (MC4R agonism) | PT-141 / Bremelanotide | Increases desire signal, central arousal, sometimes spontaneous erection in users with intact peripheral function. | Doesn’t guarantee erection on its own; doesn’t treat ED of vascular origin. |
| Central (broad melanocortin) | Melanotan II | MC1R/MC4R/MC5R agonist; libido is a side-effect of MC4R activation, alongside the tanning effect users are usually after. | Not designed for libido; effects are inconsistent and accompanied by pigmentation tradeoffs. |
| Vascular (PDE5 inhibition) | Sildenafil / tadalafil / vardenafil | Blocks PDE5 in penile vasculature, allowing cGMP accumulation and erection in response to arousal. | Doesn’t increase desire; requires central arousal already present to produce the erection. |
Practical translation: a user with normal vascular function but low desire is the natural PT-141 audience. A user with normal desire but unreliable erections is the PDE5 audience. A user with both problems can stack them - carefully, at the lower end of each dose range, because the combination is where priapism risk lives.
PT-141 protocol
- Standard dose. 1.75 mg SC, 45–90 minutes before anticipated activity. Onset is gradual; effects can persist 6–24 hours.
- Frequency caps. Vyleesi label: max 1 dose per 24 h and max 8 doses per month. Operator practice respects these because blood-pressure response and nausea track use frequency.
- Lower starting dose. 1.0–1.25 mg first time is reasonable to gauge nausea response, then move to 1.75 mg if tolerated.
- Pre-screening. Resting BP baseline. Cardiovascular history matters; PT-141 produces transient BP increases and occasional reflex bradycardia, which is the main mechanism-of-injury pathway.
- Antiemetic. Ondansetron 4 mg or cetirizine 10 mg an hour before injection cuts a chunk of the nausea for many users.
Where MT-II fits (and where it doesn’t)
- The libido side-effect is real but variable. A subset of MT-II users on tanning protocols report increased desire alongside the autonomic effects in the loading phase. After saturation / maintenance dosing, that effect fades.
- Don’t use MT-II as a primary libido tool. PT-141 was developed from MT-II precisely to isolate the libido signal from the broader melanocortin profile. Going back to MT-II for libido is going backwards on selectivity.
- Stacking MT-II + PT-141. Both are central melanocortin agonists. Stacking them at full-dose either compound is unnecessary and increases nausea / BP load. If both are on the plan (tanning + libido), space them by at least 12 hours and use the lower end of PT-141’s range.
Hard conflicts
- PT-141 / MT-II + active MAOI use. Theoretical pressor interaction. Treat as hard avoid.
- PT-141 + uncontrolled hypertension. The transient BP increase is meaningful (~6–10 mmHg systolic in trials). Stable, controlled BP is the prerequisite.
- PT-141 + recent cardiovascular event. The same-axis question PDE5 inhibitors face applies here. Wait for medical clearance, regardless of how informal the protocol is otherwise.
- Stacking PDE5 + PT-141 at high doses. Synergistic erectile effect; priapism risk if both are dosed close together at high doses. Lower the PDE5 dose first time. See Stacking Safety Quick Reference.
Decision guide
- Is the issue desire or erection?
→ Desire → PT-141.
→ Erection (with normal desire) → PDE5 first-line, not a peptide question.
→ Both → PDE5 + PT-141, low end of each dose, spaced. - Is BP controlled and cardiovascular history clean?
→ Yes → PT-141 protocol is reasonable.
→ No → address the BP / CV question first. - Currently on an MAOI?
→ Off the table for both PT-141 and MT-II. - Tested athlete?
→ PT-141 sits in the WADA grey zone; MT-II in the same bucket. Default to "treat as banned" for tested competition. See WADA Testing and Detection.
Representative stacks
Stack 1 - PT-141 on-demand (default)
- PT-141 1.75 mg SC, 45–90 min before activity, max 1/day and 8/month
- Cetirizine 10 mg or ondansetron 4 mg an hour before for nausea-prone users
- BP baseline before first use; check after each of the first 2–3 sessions
Stack 2 - PT-141 + low-dose PDE5 (combined desire + reliability)
- Stack 1 dose of PT-141
- Sildenafil 25 mg or tadalafil 5 mg, taken at the same time as PT-141 (sildenafil onset 30–60 min; tadalafil onset 60–120 min, longer duration)
- First time, halve both. Priapism risk lives at the upper end of both doses simultaneously.
- Skip alcohol on dosing day - PT-141 nausea + alcohol + PDE5 hypotension is the common stack of bad ideas
What stops people
- Treating PT-141 as a quick fix for ED. PT-141 produces desire / central arousal, not a reliable erection. Users with vascular ED who try PT-141 first usually conclude it "doesn’t work" and miss that the diagnosis was wrong.
- Stacking high-dose PT-141 + high-dose PDE5 first time. Priapism is rare but real. Lower the doses on the first combined session.
- Using MT-II for libido. Wrong tool. PT-141 was isolated from MT-II precisely because the broad melanocortin profile of MT-II creates more side effects per unit libido benefit.
- Skipping the BP baseline. The nausea is the attention-grabbing side effect, but the cardiovascular signal is where injuries actually happen. Five minutes with a home BP cuff once is the screening.
- Sourcing PT-141 with no verification. Like any grey-market peptide, counterfeits exist. PT-141 is one where underdosing produces "doesn’t work" rather than a clear side-effect signal - making bad source quality hard to distinguish from non-response. See Sourcing and Verification.
Cross-references
- Melanocortin Map - the receptor-level explanation behind PT-141 and MT-II.
- Stacking Safety Quick Reference - PDE5 + PT-141 priapism rule, MAOI conflict.
- Skin and Hair application - for users primarily on MT-II for tanning.
- WADA Testing and Detection - PT-141 / MT-II compliance for tested athletes.